Table 1. Baseline characteristics.
| General characteristics | |
| Patients | 16,185 |
| Treatment periods | 16,570 |
| Men | 8713 (53) |
| Age | 70 (14) |
| INR target range | |
| 2.5–3.5 | 15,509 (93) |
| 3.0–4.0 | 1061 (7) |
| Treatment indication | |
| Atrial fibrillation | 10,876 (66) |
| Venous thrombosis | 3920 (24) |
| Mechanical heart valves | 435 (3) |
| Ischemic heart disease | 519 (3) |
| Vascular disease | 412 (3) |
| Postoperative | 125 (1) |
| Other | 348 (2) |
| Vitamin K antagonist | |
| Phenprocoumon | 12,068 (73) |
| Acenocoumarol | 4481 (27) |
| Warfarin | 18 (0) |
| Fluindione | 3 (0) |
| Co-Medication | |
| Anti-platelet drugs | 2705 (16) |
| NSAIDs | 1004 (6) |
| Glucose lowering drugs | 8013 (48) |
| Anti-hypertensive drugs | 8354 (50) |
| Cholesterol lowering drugs | 6288 (38) |
| Digoxin | 1767 (11) |
| Anti-cancer drugs | 339 (2) |
| Opioids | 1306 (8) |
| Methotrexate | 155 (1) |